The Glicentin ELISA immunoassay kit uses highly characterized antibody pairs with precise antibody binding locations to eliminate cross-reactivity.
| Catalog Number | |
|---|---|
| Packaging | 96 well microtiter |
| Detection | HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter |
| Dynamic Range | 6, 33.3-1666 pg/mL |
| Species Reactivity | Enquire about animal-specific cross-reactivity |
| Limit of Detection | 4.17 pg/mL |
| Sample Size | 25 µL |
| Sample Type | Plasma |
| Assay Time | 2.5 hours |
| Shelf Life | 24 months |
| Availability | Worldwide |
Glicentin is a 69 amino acid N-terminal peptide derived from proglucagon (PG 1-69) by posttranslational processing in the intestine by intestinal L-cells.Glicentin can further be processed into oxyntomodulin, corresponding to proglucagon residues no 33-69. These peptides are released simultaneously upon stimulation. Glicentin is a pro-glucagon derived gut peptide that is released in the gut in response to feed intake. It is present in high levels in thecirculation after stimulation and is often a problem when measuring glucagonbecause of its shared sequence.
Glicentin
Glicentin ELISA AL-185
D’Alessio D, Kumar A, Kalra B, Mistry S, Tong J. Novel ELISA Assays Demonstrate Specificity of Islet and Intestinal Processing of Proglucagon. Volume 4, Issue Supplement_1, April_May 2020, SUN-LB124, https://doi.org/10
All Products Cited: GLP-1 ELISA AL-172; Glucagon ELISA AL-157; Oxyntomodulin ELISA AL-139; Glicentin ELISA AL-185
Kim S, Abbasi F, Nachmanoff C, Kumar A, Kalra B, Savjani G, Mantzoros C. Effect of Liraglutide Treatment on Proglucagon-Derived Peptides. JESOCI, Volume 4, Abstract Supplement, 2020
All Products Cited: GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Glucagon ELISA AL-127; Oxyntomodulin ELISA AL-139; Glicentin ELISA AL-185; MPGF ELISA AL-175
Perakakis N, Kalra B, Angelidi AM, Kumar A, Gavrieli A, MYannakoulia M, Mantzoros CS. Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial. Metabolism, Volume 129, 2022, 155157, ISSN 0026-0495, https://doi.org/10.1016/j.metabol.2022.155157.
All Products Cited: GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Oxyntomodulin ELISA AL-139; Glicentin ELISA AL-185; Glucagon ELISA AL-127; MPGF ELISA AL-175; C-Peptide of Insulin ELISA AL-151